Innovators in the Click Chemistry & Bioorthogonal Chemistry Market
- Thermo Fisher Scientific / Invitrogen (Click-iT™ portfolio)
- Merck KGaA / MilliporeSigma (Sigma-Aldrich click reagents)
- Baseclick (baseclick GmbH)
- Click Chemistry Tools (CCT)
- Jena Bioscience
- BroadPharm / Biopharma PEG (click reagent merchant)
- Lumiprobe
- Biotium, Inc.
- Glen Researc
- Alfa Chemistry
- BOC Sciences
- Biosynth (Merck/Biosynth / specialty reagents)
- TCI (Toshima Chemical Industries / TCI Americas)
- BaseClick / baseclick (if counted separately from BaseClick originators/licensing partners)
- IDT (Integrated DNA Technologies — click-enabled oligos via licensing)
- LGC (including former Biosearch Technologies/oligo & modification supply)
- SuSoS AG (surface functionalization / DBCO reagents)
- 1Click Chemistry (specialty reagent reseller & custom synthesis)
- AlphaThera / Alpha Alternatives (specialty click linkers & custom conjugation)
- Contract-service providers & specialized CDMOs offering click-chemistry services (representative examples: small molecule/bioconjugation CDMOs listed in market reports)
Market Growth
The global click chemistry & bioorthogonal chemistry market size is calculated at USD 1.02 billion in 2024, grew to USD 1.11 billion in 2025, and is projected to reach around USD 2.29 billion by 2034. The market is expanding at a CAGR of 8.65% between 2025 and 2034.
Click Chemistry & Bioorthogonal Chemistry Market Trends
Academic & Industry Collaborations
Increasing partnerships between universities, biotech firms, and CDMOs expand innovation pipelines and speed up translation into commercial products. Strategic collaborations and partnerships drive the click chemistry & bioorthogonal chemistry market by combining expertise from academia, biotech, and pharma to accelerate drug discovery, imaging, and targeted therapies. Such alliances reduce R&D costs, speed clinical adoption, and foster innovation. Recent pharma biotech partnerships advancing bioorthogonal therapeutics highlight how joint efforts expand applications and strengthen market growth opportunities worldwide.
For instance,
- In July 2025, Washington University (WashU) in St. Louis, Missouri, USA, and Merck, a prominent science and technology company, have inked a non-binding Memorandum of Understanding (MoU). In a partnership spanning almost a century, the agreement ushers in the next phase of scientific innovation and research.
Expansion of Product Range & Market Expansion
The expansion of product range and market reach drives the growth of the click chemistry & bioorthogonal chemistry market by enabling companies to cater to broader research and clinical needs. Introducing diverse reagents, probes, and kits enhances accessibility for applications in drug discovery, molecular imaging, and diagnostics. Market expansion into emerging regions increases adoption, fosters collaborations, and opens new revenue opportunities, accelerating overall industry growth.
For instance,
- In February 2024, Alfa Chemistry, a leading chemical supplier and service provider, announced the expansion of its selection of click chemistry reagents. The goal of this advancement is to better meet the needs of scientists and researchers engaged in click chemistry, a potent technique for rapidly and effectively assembling intricate molecular structures. Click chemistry has gained significant attention and popularity in recent years due to its versatility and reliability. Carefully joining tiny building blocks enables scientists to create new molecular entities.
Establishment of Bioorthogonal Nanozymes & Smart Materials: Stimuli-responsive catalysts (“nanozymes”) are emerging for controlled, in-vivo-compatible reactions and sensing. By 2025, developments in smart materials and bioorthogonal nanozymes are anticipated to see further advancements and possible medical uses, especially in targeted drug delivery and diagnostics. The growing demand for precision medicine to transform healthcare is the driving force behind these advancements.
Kits, Catalogs & Workflow Simplification: Vendors are expanding ready-to-use tetrazines, TCOs, strained alkynes, and copper-free labeling kits to push click deeper into routine bioanalytics and imaging. (Inference based on the above market adoption reviews and segment growth.)
Latest Announcement by Industry Leaders
In July 2025, Anand Nambiar, Head of Science & Lab Solutions for the Life Science business sector of Merck, stated that the clients of the company are looking forward to instruments that increase productivity and provide consistent, repeatable results. The Merck company is dedicated to providing scientists with tools that streamline their processes and improve their capacity for research is very well demonstrated by the AAW platform. Click chemistry can be indirectly supported by the AAW automated assay workstation by automating the assay and sample, magnetic bead purification, heating, shaking, and handling liquid.
Recent Developments in the Click Chemistry & Bioorthogonal Chemistry Market
- In June 2025, Shasqi, Inc., a biotech company, revealed that the company has a goal of producing medications to treat cancer using click chemistry. The preclinical development and translation of SQ3370 to a first-in-human dose-escalation clinical trial in patients with advanced solid tumors was described in a manuscript published. Click chemistry made pre-targeting more effective. A first-in-class click chemistry-based cancer treatment: From preclinical assessment to a first-in-class treatment. The American Association for Cancer Research’s journal, Clinical Cancer Research, published a human dose escalation clinical trial (AACR) research.
- In December 2024, VERAXA Biotech AG, a new pioneer in the development of innovative cancer treatments, and Navigo Proteins GmbH, a pioneer in the development of next-generation targeted radiotheranostics, announced the start of a research partnership to assess a new method for accurately identifying and treating difficult cancers while minimizing harm to healthy tissues Radioimmunoconjugates (RICs) are used. Through the agreement, VERAXA's proprietary click chemistry platform and conjugation expertise are combined with Navigo Protein's Affilin platform, which offers highly specific targeted radiotheranostics.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
